Stockreport

Stoke Therapeutics: A Long-Term Biotech Growth Play - Why I Assign A Hold Rating [Seeking Alpha]

Stoke Therapeutics, Inc.  (STOK) 
Last stoke therapeutics, inc. earnings: 11/12 08:00 am Check Earnings Report
PDF I assign a HOLD rating, as STOK's pipeline is promising but high-risk, with significant milestones and regulatory hurdles ahead. The Biogen partnership secures fundin [Read more]